IntrinsicIntrinsic
← All summaries

Greenland Mines Ltd

GRML
Financials & Chart →

Business Summary

Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) is a company focused on developing essential medicines for chronic diseases, including cancer, cardiovascular, and neurodegenerative disorders. The company operates through two primary licensed platforms: a generic drug portfolio and a biosimilar biologics platform for cancer treatment, and a proprietary, patented gene therapy platform utilizing the "Klotho" protein for neurodegenerative diseases. A significant strategic development occurred in March 2026, subsequent to the reported fiscal year, with the acquisition of Greenland Mines Corp., expanding operations into the development and mining of critical and precious minerals. The company's common stock and warrants trade on the Nasdaq under the symbols "GRML" and "GRMLW" respectively.

The core business model revolves around the research, development, and eventual commercialization of pharmaceutical products. This includes a mix of generic drugs, biosimilar biologics, and novel gene therapies. The primary customer segments, once products are commercialized, would be patients suffering from chronic diseases such as cancer, Alzheimer's disease, and Amyotrophic Lateral Sclerosis (ALS). The company currently generates no revenue, indicating a pre-commercialization stage business model heavily reliant on successful R&D and regulatory approvals.

The company's product and service lines are segmented into three main areas. First, a generic drug portfolio includes five market-approved anti-cancer drugs, four of which are part of the "FOLFOX" and "FOLFIRI" multi-drug regimens for metastatic colorectal and gastric cancer, and two used for metastatic lung cancer. These drugs are approved for sale in Germany . Second, a biosimilar biologics platform, in-licensed from Reliance Life Sciences (RLS), focuses on "off-patent" biosimilar versions of Roche's rituximab (MabThera®/Rituxan®), trastuzumab (Herceptin®), and bevacizumab (Avastin®) for cancer, autoimmune diseases, and neovascularization diseases . The licensed territory for these biosimilars is North America, Europe, and Israel . Third, a proprietary, patented gene therapy platform utilizes a gene therapy approach to introduce the therapeutic protein "Klotho" to treat neurodegenerative diseases and other age-related disorders. This platform includes two lead product candidates: KLTO-101 (AAV9-CMV-sKL) for Alzheimer's disease and KLTO-202 (AAVmyo-Des-sKL) for ALS . The company also holds a license for a "Needleless Syringe" technology .

For the fiscal year ended December 31, 2025, Greenland Mines Ltd reported no revenue . The company incurred a net loss of $10,551,674 . Operating expenses totaled $7,146,265 . Cash and cash equivalents stood at $7,176,615 , with total current assets of $7,293,686 and total current liabilities of $76,764 , resulting in a working capital of $7,216,922 . The accumulated deficit as of December 31, 2025, was approximately $21.1 million .

Comparing fiscal year 2025 to 2024, the company's operating expenses increased by $1,606,029 , from $5,540,236 in 2024 to $7,146,265 in 2025 . This increase was primarily driven by a $1,381,590 rise in general and administrative expenses , a $634,187 increase in research and development expense , and a $674,613 increase in professional fees , partially offset by a $1,084,361 decrease in stock-based compensation expense . The net loss widened from $6,150,372 in 2024 to $10,551,674 in 2025 . Net cash used in operating activities increased by $2,942,742 , from $2,946,512 in 2024 to $5,889,254 in 2025 . Cash and cash equivalents increased significantly from $63,741 in 2024 to $7,176,615 in 2025 , primarily due to $13,002,128 in net cash provided by financing activities in 2025, compared to $3,130,942 in 2024 .

During the reported period, the company made several operational developments. It initiated a warrant exercise inducement program, reducing the exercise price from $3.49 to $1.35 for certain outstanding warrants . This resulted in the exercise of 11.0 million warrants for gross proceeds of $11.4 million . The company also entered into a securities purchase agreement with an accredited investor, issuing 6,250,000 shares of common stock at $0.08 per share for gross proceeds of $500,000 . Additionally, 500 preferred B shares were issued for $500,000 and subsequently converted into 6,250,000 common shares . The company also entered into an At-the-Market sales agreement to sell up to $50,000,000 of common stock, selling 2,206,930 shares for gross proceeds of $1,112,745 in 2025 . A Share Exchange Agreement to acquire SB Security Holdings, LLC was terminated on June 13, 2025 .

Business Outlook

Management explicitly states that the company has not generated any revenue to date and does not expect to generate product revenue unless and until it successfully completes development and obtains regulatory approval for at least one of its gene therapy product candidates . The company expects to continue to incur significant operating and net losses, as well as negative cash flows from operations, for the foreseeable future as it continues to develop its gene therapy product candidates and prepare for potential future regulatory approvals and commercialization of its products . The current cash and cash equivalents balance will not be sufficient to complete all necessary development activities and commercially launch products .

A major growth area for the company is its proprietary, patented gene therapy platform, which uses a gene therapy approach to introduce the therapeutic protein "Klotho" to treat neurodegenerative diseases. The two lead product candidates are KLTO-101 (AAV9-CMV-sKL) for Alzheimer's disease and KLTO-202 (AAVmyo-Des-sKL) for Amyotrophic Lateral Sclerosis (ALS) . The company plans to complete the animal toxicology package for KLTO-202 and submit an Investigational New Drug (IND) application to the FDA in 2025 for a first-in-human Phase I "Compassionate Use" study in late-stage ALS patients . The pre-clinical development program for KLTO-101 is expected to follow KLTO-202 by six to nine months . The company intends to seek market approval in countries where it has issued and/or pending patents, including the U.S., Canada, Europe, China, and other viable markets . Furthermore, the company plans to find a corporate partner for the development of KLTO-101 for Alzheimer's disease . There is also a plan to develop and validate new in vitro assays to separate and individually measure the three Klotho protein isoforms (s-KL, m-KL, p-KL) and two metabolites (KL1 and KL2) as part of the research and development program .

Another growth area is the biosimilar biologics platform, which includes "off-patent" biosimilar versions of rituximab, trastuzumab, and bevacizumab for cancer and other diseases . The company has initiated preparatory activities for its confirmatory Phase 3 clinical trial of bevacizumab-anew (Avastin) biosimilar candidate and rituximab-anew (Rituxan/Mabthera) candidate . The company expects it may be several years before these Phase 3 clinical trials are completed and a product candidate is ready for market approval .

The company expects net cash used in operating activities to increase in the future until its products are able to produce meaningful revenue . The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue executing its development plans and operations . Without additional funding, there is substantial doubt about the company's ability to continue as a going concern for the twelve months from the date of the financial statements .

Regarding capital allocation, the company has an Equity Incentive Plan, and during 2025, it granted 180,000 stock options at a weighted average fair value of $0.38 and 408,691 shares at $1.34 per share to a member of management . In 2024, 1,000,000 stock options were granted at a weighted average fair value of $0.37 . The company also entered into an At-the-Market sales agreement to sell up to $50,000,000 of common stock, intending to use the net proceeds for working capital and general corporate purposes .

The company faces structural headwinds and execution risks, including the need for substantial additional funding to meet financial obligations and pursue business objectives . It is highly dependent on collaborations with Universitat Autònoma de Barcelona (UAB) for preclinical R&D programs . Negative public opinion of gene therapy and increased regulatory scrutiny may adversely impact development or commercial success . The company faces significant competition in biosimilar biologics from other biotechnology and pharmaceutical companies . There is also a risk that other companies may have property rights to the AAV and lentiviral vectors and lipid nanoparticles used for gene therapies, which the company may need to license . The company currently has no products approved for commercial sale and may never be able to develop marketable products .

Risk Factors

Greenland Mines Ltd faces substantial risks across macroeconomic, competitive, regulatory, and operational dimensions. Macroeconomic risks include the company's reliance on outside financing and cash from operations, with no assurance of securing timely additional financing on favorable terms, or at all, which could significantly limit its ability to grow or support its business . Operationally, the company has incurred significant losses since its inception and expects to continue incurring losses and negative cash flows for the foreseeable future, raising substantial doubt about its ability to continue as a going concern without additional funding . The company is highly dependent on its key executives and personnel, and the loss of any of these individuals could seriously harm its business . Furthermore, the company relies on third parties for manufacturing, quality control testing, and conducting preclinical and clinical trials, and any failure by these third parties to comply with regulations or meet supply demands could harm the business . In terms of competitive risks, the company expects to enter highly competitive pharmaceutical markets, facing numerous companies with substantially greater financial, technical, and other resources, including larger R&D staff and experienced marketing and manufacturing organizations . Specifically, for biosimilars, there are already at least four approved bevacizumab biosimilars and three approved rituximab biosimilars on the market, which could materially harm the company's ability to gain market share . Regulatory risks are significant, as the evolving regulatory approval processes for biologics and gene therapies are lengthy, time-consuming, rigorous, and inherently unpredictable, with no guarantee of obtaining approval for any product candidates . The company's gene therapy product candidates are based on new gene transfer technology, making it difficult to predict the time and cost of development and regulatory approval . Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception or adversely affect the ability to conduct business or obtain regulatory approvals . The company also faces a NASDAQ delisting risk due to its common stock failing to maintain a minimum bid price of $1 per share for 30 consecutive business days, with an extension granted until September 14, 2026, to regain compliance .

Management Priorities

Management's message to shareholders emphasizes the company's focus on developing essential medicines for chronic diseases, particularly through its gene therapy platform for neurodegenerative disorders and biosimilar biologics for cancer. They acknowledge the significant strategic shift with the recent acquisition of Greenland Mines Corp. in March 2026, expanding into critical and precious mineral mining, which is noted as a "significant step in the Company's strategic growth and positioning" . However, the financial discussion in the 10-K does not reflect the impact of this acquisition. Management explicitly states that the company has not generated any operating revenues to date and does not expect to generate product revenue unless and until it successfully completes development and obtains regulatory approval for at least one of its gene therapy product candidates . They anticipate continued significant operating and net losses and negative cash flows for the foreseeable future . A key strategic priority is the advancement of the cell and gene therapy product candidates, specifically KLTO-101 for Alzheimer's disease and KLTO-202 for ALS, with plans to complete the animal toxicology package for KLTO-202 and submit an IND application to the FDA in 2025 for a Phase I "Compassionate Use" study . Another priority is to find a corporate partner for the development of KLTO-101 . Management also highlights the ongoing development of a new assay method to differentiate Klotho protein isoforms as part of the R&D program . They also note the need for substantial additional funding to meet financial obligations and pursue business objectives, indicating that current cash and cash equivalents are insufficient to complete all necessary development and commercialization activities .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Our Research Pipeline
  3. [3] Item 1, Business — Biosimilars Program
  4. [4] Item 1, Business — Our two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis or “ALS”).
  5. [5] Item 4, Intangible Assets — Needleless Syringe License
  6. [6] Item 7, MD&A — Revenue
  7. [7] Item 7, MD&A — Net Loss
  8. [8] Item 7, MD&A — Operating Expenses
  9. [9] Item 7, MD&A — Liquidity and Capital Resources
  10. [10] Item 8, Consolidated Balance Sheets — Total current assets
  11. [11] Item 8, Consolidated Balance Sheets — Total current liabilities
  12. [12] Item 7, MD&A — Working Capital
  13. [13] Item 2, Summary of Significant Accounting Policies — Going Concern
  14. [14] Item 7, MD&A — Operating Expenses
  15. [15] Item 7, MD&A — Operating Expenses
  16. [16] Item 7, MD&A — Operating Expenses
  17. [17] Item 7, MD&A — Operating Expenses
  18. [18] Item 7, MD&A — Operating Expenses
  19. [19] Item 7, MD&A — Operating Expenses
  20. [20] Item 7, MD&A — Operating Expenses
  21. [21] Item 7, MD&A — Net Loss
  22. [22] Item 7, MD&A — Net Loss
  23. [23] Item 7, MD&A — Operating Activities
  24. [24] Item 7, MD&A — Operating Activities
  25. [25] Item 7, MD&A — Operating Activities
  26. [26] Item 7, MD&A — Liquidity and Capital Resources
  27. [27] Item 7, MD&A — Liquidity and Capital Resources
  28. [28] Item 7, MD&A — Financing Activities
  29. [29] Item 7, MD&A — Financing Activities
  30. [30] Item 9, Stockholder's Equity — Warrants
  31. [31] Item 9, Stockholder's Equity — Warrants
  32. [32] Item 9, Stockholder's Equity — Investor Share Purchase
  33. [33] Item 9, Stockholder's Equity — Preferred B Shares
  34. [34] Item 9, Stockholder's Equity — At-the-Market Sales Agreement
  35. [35] Item 10, Commitments and Contingencies — Termination of acquisition agreement of SB Security Holdings, LLC
  36. [36] Item 1A, Risk Factors — We currently have no products that are approved for commercial sale and may never be able to develop marketable products.
  37. [37] Item 1A, Risk Factors — We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.
  38. [38] Item 1A, Risk Factors — We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.
  39. [39] Item 1, Business — Our two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis or “ALS”).
  40. [40] Item 1, Business — Our two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis or “ALS”).
  41. [41] Item 1, Business — Our two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis or “ALS”).
  42. [42] Item 1, Business — The Company plans to seek market approval in countries where we have issued and/or pending patents, to include the U.S., Canada, Europe, China, and other viable markets.
  43. [43] Item 1, Business — We plan to find a corporate partner to help in the development of KLTO-101 for the Alzheimer’s disease indication.
  44. [44] Item 1, Business — Therefore, as part of the research and development (R&D) program, we plan to develop and validate an assay to separate and individually measure all Klotho isoforms and metabolites of p-KL.
  45. [45] Item 1, Business — Our clinical-stage generic/biosimilar technologies consist of (a) “off-patent” portfolio of generic drugs (b) and “off-patent” biosimilar biologics (in-licensed from RLS).
  46. [46] Item 1A, Risk Factors — If we are unable to obtain regulatory approval for, or successfully commercialize, bevacizumab-anew, or rituximab-anew, our business will be harmed.
  47. [47] Item 1A, Risk Factors — If we are unable to obtain regulatory approval for, or successfully commercialize, bevacizumab-anew, or rituximab-anew, our business will be harmed.
  48. [48] Item 7, MD&A — Operating Activities
  49. [49] Item 2, Summary of Significant Accounting Policies — Going Concern
  50. [50] Item 2, Summary of Significant Accounting Policies — Going Concern
  51. [51] Item 9, Stockholder's Equity — Equity Incentive Plan
  52. [52] Item 9, Stockholder's Equity — Equity Incentive Plan
  53. [53] Item 9, Stockholder's Equity — Equity Incentive Plan
  54. [54] Item 9, Stockholder's Equity — At-the-Market Sales Agreement
  55. [55] Item 1A, Risk Factors — We will need substantial additional funding to meet our financial obligations and to pursue our business objectives.
  56. [56] Item 1A, Risk Factors — We currently primarily rely on our collaborations with Universitat Autònoma de Barcelona (“UAB”) for our preclinical research and development programs.
  57. [57] Item 1A, Risk Factors — Negative public opinion of gene therapy and increased regulatory scrutiny of gene therapy and genetic research may adversely impact the development or commercial success of our current and future product candidates.
  58. [58] Item 1A, Risk Factors — We face significant competition in the area of biosimilar biologics from other biotechnology and pharmaceutical companies.
  59. [59] Item 1A, Risk Factors — We use AAV and lentiviral vectors, and lipid nanoparticles to deliver some gene therapies, but others may have property rights to these vectors that we may need to license.
  60. [60] Item 1A, Risk Factors — We currently have no products that are approved for commercial sale and may never be able to develop marketable products.
  61. [61] Item 1A, Risk Factors — We may need additional capital in the future, which may not be available to us on favorable terms, and may dilute your ownership of our common stock.
  62. [62] Item 1A, Risk Factors — We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.
  63. [63] Item 1A, Risk Factors — We are highly dependent on the services of our key executives and personnel, including our Chief Executive Officer, Dr. Joseph Sinkule (Pharm. D.) and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.
  64. [64] Item 1A, Risk Factors — We will rely on third parties to manufacture and quality control test our product candidates, to conduct our preclinical and clinical trials, and perform other tasks for us.
  65. [65] Item 1A, Risk Factors — We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, more effective, or less expensive than ours.
  66. [66] Item 1A, Risk Factors — We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, more effective, or less expensive than ours.
  67. [67] Item 1A, Risk Factors — The evolving regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time-consuming, rigorous, and inherently unpredictable. If we and our collaboration partners are ultimately unable to obtain regulatory approval for our product candidates, our business will be harmed.
  68. [68] Item 1A, Risk Factors — Our AAV-based gene therapy product candidates and our lentiviral-based gene therapy product candidate are based on new gene transfer technology, which makes it difficult to predict the time and cost of product candidate development and of subsequently obtaining regulatory approval.
  69. [69] Item 1A, Risk Factors — Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.
  70. [70] Item 1A, Risk Factors — If we fail to comply with the continued listing requirements of Nasdaq, specifically, Nasdaq Listing Rule 5450(a)(2), we may face possible delisting, which would result in a limited public market for our shares and make obtaining future debt or equity financing more difficult for us.
  71. [71] Item 1, Business — Overview
  72. [72] Item 7, MD&A — Overview
  73. [73] Item 7, MD&A — Overview
  74. [74] Item 1, Business — Our two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis or “ALS”).
  75. [75] Item 1, Business — We plan to find a corporate partner to help in the development of KLTO-101 for the Alzheimer’s disease indication.
  76. [76] Item 1, Business — Therefore, as part of the research and development (R&D) program, we plan to develop and validate an assay to separate and individually measure all Klotho isoforms and metabolites of p-KL.
  77. [77] Item 1A, Risk Factors — We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates.

Analysis on 5/21/2026